Treating inflammation with the Janus kinase inhibitor CP-690,550.
about
Next-Generation Therapeutics for IBDRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorFunctional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.Small-molecule control of cytokine function: new opportunities for treating immune disordersTreating Alopecia Areata: Current Practices Versus New Directions.Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedbackWedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein dephosphorylation.The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.Tofacitinib.Targeting inflammatory pathways in chronic lymphocytic leukemia.Nuclear JAK2: form and function in cancer.Psoriasis drug discovery: methods for evaluation of potential drug candidates.Current and emerging systemic treatment strategies for psoriasis.Emerging immunosuppressive drugs in myelodysplastic syndromes.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis.Overcoming immunological barriers in regenerative medicine.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text MiningRegulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitorsEffect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.Novel treatments for inflammatory bowel disease.Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays.Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3.Energy-sensitive regulation of Na+/K+-ATPase by Janus kinase 2.Efficacy of tofacitinib in treatment of alopecia universalis in two patients.Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils
P2860
Q28082306-DCEEF237-2C6F-4A80-B6CF-BDA0B615A7D8Q28482297-9514D206-BFD6-4583-96F0-E1FD55970014Q35072638-194C3D03-350B-4E59-AF31-01E3BB0A9EE3Q35178124-93C74E1D-87FD-443B-9C85-EAB929B25305Q35252669-95E89EF5-28C7-4BE4-A715-150EB4A1FD1AQ36171921-E463525D-8715-43CF-B784-65FDC56CAFE4Q36238033-B456CC5D-E365-4D8F-9DBF-6B7BB33C6ACDQ36850338-C5FA20AD-8FF0-4845-97EA-3232A87EB258Q37039005-4E011BD2-B053-4D45-8302-160EEF55E5CDQ37340011-32402D97-02B0-4BEB-958C-A225B9A05DC2Q37351312-DA1341DD-F720-4C8B-8C7D-B9233B8CF0F6Q37910092-CCF59605-35B4-4800-BDE7-C263D59EBD0CQ37999088-C80C14AF-F98F-4F84-9276-4B17AD78EA81Q38039491-89D472F8-C425-4904-BD2C-D95FD7C571FFQ38060835-3747807F-55FD-430D-B52F-9E881FC947ECQ38251801-F0E743EA-509F-41CA-B806-0432A2C91843Q38751230-68DD7FF6-D5DF-42E4-83FE-77C536FDEC0BQ39154718-1C1B1241-E55D-40C8-942D-06042C1AE3DBQ39948888-27542FE3-53DB-4E36-8C01-7BFDDCF1A77CQ40543038-E3082F95-D40B-4086-8410-5B98235B4E6BQ41893567-42D4E3A4-B0B1-4757-84D2-FB13BEC55340Q44028421-829E06C0-3CDA-4340-96E8-D80A47082220Q45036817-9A1641CF-CC84-4AAC-86B1-08451C9BC46CQ47563211-6CE2DCCF-53F7-4109-81EA-3C6A622791E0Q47765822-04D10581-9B72-413D-A1CA-218803E63F64Q48575707-46657C0A-7742-4311-ABCC-02B7C5CE4B89Q48613326-A0F7FCB4-B993-4628-B3A9-7728A0DA6031Q54189934-C4C429D7-5D76-4632-ADE4-2F73AE10D9A2Q58694864-3CE8B666-04DC-46ED-A6EC-A4686B6D3D4A
P2860
Treating inflammation with the Janus kinase inhibitor CP-690,550.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@en
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@nl
type
label
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@en
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@nl
prefLabel
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@en
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@nl
P2093
P1476
Treating inflammation with the Janus kinase inhibitor CP-690,550.
@en
P2093
Lalitha Vijayakrishnan
Palak Gulati
R Venkataramanan
P356
10.1016/J.TIPS.2010.10.004
P577
2010-12-07T00:00:00Z